Roche Is Discussing Alzheimer’s Drug With FDA Following Regulator’s Controversial Approval Of Biogen’s Aduhelm, CEO Says Aduhelm is expected to be a bestseller for Biogen and was the first Alzheimer’s drug to be granted “accelerated approval,” a decision the regulator’s experts criticized and said there was not enough evidence the drug actually worked.